Multiple Myeloma
Conditions
Interventions
treatment Group:Maintenance therapy with daratumumab+lenalidomide/pomalidomide after autologous transplantation
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed high-risk multiple myeloma patients, 2. Age between 18-75 years old, 3.Willing to come back for necessary follow-up visits.
Exclusion criteria
Exclusion criteria: 1.Other serious diseases that may limit the patient's participation in this trial (such as advanced infection, uncontrolled diabetes, severe cardiac insufficiency or angina, severe liver function abnormalities, etc.); 2. Patients who are participating in other clinical trials; 3. Unable to understand or comply with the study protocol; 4. Other conditions that the investigator considers unsuitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free Survival;Overall Response Rate;Adverse Event Frequency ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival;Adverse Event Types;Adverse Event Severity ; | — |
Countries
China
Contacts
Public ContactZeng Qiang
West China Hospital, Sichuan University
Outcome results
None listed